Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
The agreement will facilitate the establishment of the IITK-UB Joint Center of Excellence in Biomedicine and Bioengineering
Essex enriches and complements Emmes’ services
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
She joins Enveda from Gilead Sciences
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Subscribe To Our Newsletter & Stay Updated
